Beau B Bruce1, Kathleen B Digre2, Michael P McDermott2, Eleanor B Schron2, Michael Wall2. 1. From the Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; Departments of Neurology and Ophthalmology (K.B.D.), Moran Eye Center, University of Utah, Salt Lake City; Departments of Biostatistics and Computational Biology and Neurology (M.P.M.), University of Rochester Medical Center, NY; Division of Extramural Research (E.B.S.), National Eye Institute, Bethesda, MD; and Department of Ophthalmology and Visual Sciences (M.W.), University of Iowa Carver College of Medicine, Iowa City. bbbruce@emory.edu. 2. From the Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; Departments of Neurology and Ophthalmology (K.B.D.), Moran Eye Center, University of Utah, Salt Lake City; Departments of Biostatistics and Computational Biology and Neurology (M.P.M.), University of Rochester Medical Center, NY; Division of Extramural Research (E.B.S.), National Eye Institute, Bethesda, MD; and Department of Ophthalmology and Visual Sciences (M.W.), University of Iowa Carver College of Medicine, Iowa City.
Abstract
OBJECTIVE: To examine the changes in vision-specific and overall health-related quality of life (QOL) at 6 months in participants with idiopathic intracranial hypertension (IIH) and mild visual loss enrolled in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) and to determine the signs and symptoms of IIH that mediate the effect of acetazolamide on QOL. METHODS: We assessed QOL using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25), the 10-Item NEI-VFQ-25 Neuro-Ophthalmic Supplement, and the 36-Item Short Form Health Survey (SF-36). We examined associations among changes in QOL measures over 6 months, treatment status, and changes in signs and symptoms using linear and structural equation models. RESULTS: Among the 165 participants with IIH (86 randomized to acetazolamide, 79 to placebo), beneficial effects of acetazolamide were seen on all QOL scales evaluated, as well as on the Near Activities (5.60 points, p = 0.03), Social Functioning (3.85 points, p = 0.04), and Mental Health (9.82, p = 0.04) subscales of the NEI-VFQ-25. Positive acetazolamide-related effects on QOL appeared to be primarily mediated by improvements in visual field, neck pain, pulsatile tinnitus, and dizziness/vertigo that outweighed the side effects of acetazolamide. CONCLUSIONS: The marked reductions in baseline QOL seen among patients with mild visual loss from IIH are improved by treatment with acetazolamide. When combined with acetazolamide-associated improvements in visual field and other aspects of IIH, our findings with respect to QOL provide further support from the IIHTT in favor of acetazolamide to augment a dietary intervention in the treatment of IIH with mild visual loss (clinicaltrials.gov: NCT01003639).
OBJECTIVE: To examine the changes in vision-specific and overall health-related quality of life (QOL) at 6 months in participants with idiopathic intracranial hypertension (IIH) and mild visual loss enrolled in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) and to determine the signs and symptoms of IIH that mediate the effect of acetazolamide on QOL. METHODS: We assessed QOL using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25), the 10-Item NEI-VFQ-25 Neuro-Ophthalmic Supplement, and the 36-Item Short Form Health Survey (SF-36). We examined associations among changes in QOL measures over 6 months, treatment status, and changes in signs and symptoms using linear and structural equation models. RESULTS: Among the 165 participants with IIH (86 randomized to acetazolamide, 79 to placebo), beneficial effects of acetazolamide were seen on all QOL scales evaluated, as well as on the Near Activities (5.60 points, p = 0.03), Social Functioning (3.85 points, p = 0.04), and Mental Health (9.82, p = 0.04) subscales of the NEI-VFQ-25. Positive acetazolamide-related effects on QOL appeared to be primarily mediated by improvements in visual field, neck pain, pulsatile tinnitus, and dizziness/vertigo that outweighed the side effects of acetazolamide. CONCLUSIONS: The marked reductions in baseline QOL seen among patients with mild visual loss from IIH are improved by treatment with acetazolamide. When combined with acetazolamide-associated improvements in visual field and other aspects of IIH, our findings with respect to QOL provide further support from the IIHTT in favor of acetazolamide to augment a dietary intervention in the treatment of IIH with mild visual loss (clinicaltrials.gov: NCT01003639).
Authors: Michael Wall; Michael P McDermott; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Mark J Kupersmith Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Michael Wall; Mark J Kupersmith; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Michael P McDermott Journal: JAMA Neurol Date: 2014-06 Impact factor: 18.302
Authors: Kathleen B Digre; Beau B Bruce; Michael P McDermott; Kristin M Galetta; Laura J Balcer; Michael Wall Journal: Neurology Date: 2015-05-20 Impact factor: 9.910
Authors: Brian A Raphael; Kristin M Galetta; Dina A Jacobs; Clyde E Markowitz; Grant T Liu; M Ligia Nano-Schiavi; Steven L Galetta; Maureen G Maguire; Carol M Mangione; Denise R Globe; Laura J Balcer Journal: Am J Ophthalmol Date: 2006-10-13 Impact factor: 5.258
Authors: M Kosinski; M S Bayliss; J B Bjorner; J E Ware; W H Garber; A Batenhorst; R Cady; C G H Dahlöf; A Dowson; S Tepper Journal: Qual Life Res Date: 2003-12 Impact factor: 4.147
Authors: Martin W ten Hove; Deborah I Friedman; Anil D Patel; Isabella Irrcher; Michael Wall; Michael P McDermott Journal: J Neuroophthalmol Date: 2016-03 Impact factor: 3.042
Authors: Steffi Weidt; Annette B Bruehl; Dominik Straumann; Stefan C A Hegemann; Gerhard Krautstrunk; Michael Rufer Journal: BMC Health Serv Res Date: 2014-07-22 Impact factor: 2.655
Authors: Christopher S Hong; Adam J Kundishora; Aladine A Elsamadicy; Eugenia M Vining; R Peter Manes; Sacit Bulent Omay Journal: J Neurol Surg B Skull Base Date: 2021-03-08
Authors: Abdulaziz H Alanazi; Mir S Adil; Xiaorong Lin; Daniel B Chastain; Andrés F Henao-Martínez; Carlos Franco-Paredes; Payaningal R Somanath Journal: Pathogens Date: 2022-07-10
Authors: Susan P Mollan; Brendan Davies; Nick C Silver; Simon Shaw; Conor L Mallucci; Benjamin R Wakerley; Anita Krishnan; Swarupsinh V Chavda; Satheesh Ramalingam; Julie Edwards; Krystal Hemmings; Michelle Williamson; Michael A Burdon; Ghaniah Hassan-Smith; Kathleen Digre; Grant T Liu; Rigmor Højland Jensen; Alexandra J Sinclair Journal: J Neurol Neurosurg Psychiatry Date: 2018-06-14 Impact factor: 10.154